Pfizer (PFE), Merck (MRK) Announce Ertugliflozin Phase 3 Met Primary Endpoint in T2D

Merck and Pfizer Announce Investigational Ertugliflozin Met Primary Endpoint of A1C Reduction When Added to Sitagliptin and Metformin in People with Type 2 Diabetes

New Phase 3 Data Presented at the European Association for the Study of Diabetes Annual Meeting Study Achieved Primary and All Key Secondary Endpoints

KENILWORTH, N.J., & NEW YORK--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United... More